HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sheng-Bin Peng Selected Research

LY3009120

1/2020A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
9/2017Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
2/2017LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
3/2016Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
9/2015Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
5/2015Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sheng-Bin Peng Research Topics

Disease

21Neoplasms (Cancer)
10/2020 - 02/2005
5Melanoma (Melanoma, Malignant)
01/2020 - 08/2012
4Neoplasm Metastasis (Metastasis)
10/2020 - 11/2005
4Colorectal Neoplasms (Colorectal Cancer)
10/2020 - 02/2017
3Carcinogenesis
01/2016 - 11/2005
2Lymphoma (Lymphomas)
01/2016 - 02/2015
2Breast Neoplasms (Breast Cancer)
02/2015 - 03/2004
1Adenocarcinoma of Lung
01/2020
1Lung Neoplasms (Lung Cancer)
01/2020
1Thyroid Neoplasms (Thyroid Cancer)
03/2016
1Hematologic Neoplasms (Hematological Malignancy)
01/2016
1Leukemia
01/2016
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
07/2015
1Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2015
1Colonic Neoplasms (Colon Cancer)
02/2015
1Renal Cell Carcinoma (Grawitz Tumor)
02/2015
1Hypertension (High Blood Pressure)
11/2011
1Pathologic Processes
11/2005
1Carcinoma (Carcinomatosis)
04/2005
1Fibrosis (Cirrhosis)
02/2005

Drug/Important Bio-Agent (IBA)

6LY3009120IBA
01/2020 - 05/2015
5Phosphotransferases (Kinase)IBA
03/2016 - 04/2005
4LY2510924IBA
01/2020 - 02/2015
4VemurafenibIBA
03/2016 - 08/2012
3Biomarkers (Surrogate Marker)IBA
01/2020 - 11/2005
3Chemokine ReceptorsIBA
01/2016 - 11/2005
3ChemokinesIBA
01/2016 - 09/2008
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2020 - 01/2020
2Peptides (Polypeptides)IBA
01/2020 - 11/2017
2LY2624587IBA
11/2017 - 01/2016
2Cyclin D1IBA
05/2015 - 10/2014
2Cyclin-Dependent Kinases (cdk Proteins)IBA
05/2015 - 10/2014
2Chemokine CXCL12IBA
02/2015 - 04/2005
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
08/2012 - 11/2011
2Proteins (Proteins, Gene)FDA Link
04/2005 - 03/2004
1MicroRNAs (MicroRNA)IBA
10/2020
1durvalumabIBA
01/2020
1LY3214996IBA
01/2020
1Immune Checkpoint InhibitorsIBA
11/2017
1Cetuximab (Erbitux)FDA Link
09/2017
1Monoclonal AntibodiesIBA
01/2016
1Guanosine Triphosphate (GTP)IBA
01/2016
1Protein Isoforms (Isoforms)IBA
09/2015
1CXC ChemokinesIBA
07/2015
1Urea (Carbamide)FDA LinkGeneric
05/2015
1dabrafenibIBA
05/2015
1Cyclic PeptidesIBA
02/2015
1abemaciclibIBA
10/2014
1UbiquitinIBA
01/2014
1Messenger RNA (mRNA)IBA
01/2014
1Ligases (Synthetase)IBA
01/2014
1Histone MethyltransferasesIBA
01/2014
1Small Interfering RNA (siRNA)IBA
01/2014
1Mitogen-Activated Protein KinasesIBA
08/2012
12- (4- (2- (5- (1- (3,5- dichloropyridin- 4- yl)ethoxy)- 1H- indazol- 3yl)vinyl)- 1H- pyrazol- 1- yl)ethanolIBA
11/2011
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2011
1Tyrosine (L-Tyrosine)FDA Link
11/2011
1NF-kappa B (NF-kB)IBA
09/2008
1Epidermal Growth Factor (EGF)IBA
09/2008
1Calcium-Sensing ReceptorsIBA
11/2005
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
11/2005
1Purinergic P2Y ReceptorsIBA
11/2005
1Proteinase-Activated ReceptorsIBA
11/2005
1Endothelin Receptors (Endothelin Receptor)IBA
11/2005
1Neuropeptide Receptors (Neuropeptide Receptor)IBA
11/2005
1Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA
11/2005
1Lysophosphatidic Acid ReceptorsIBA
11/2005
1Adenosine A2B ReceptorIBA
11/2005
12- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
04/2005
1Phosphatidylinositols (Phosphatidylinositol)IBA
04/2005
1LigandsIBA
04/2005
1WortmanninIBA
04/2005
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
04/2005
1U 0126 (UO 126)IBA
04/2005
12- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA
04/2005
1MitogensIBA
04/2005
1Transforming Growth Factor beta (TGF-beta)IBA
02/2005
1PyrazolesIBA
02/2005
1LY 475776IBA
03/2004

Therapy/Procedure

5Therapeutics
01/2020 - 10/2014
1Precision Medicine
01/2020
1Drug Therapy (Chemotherapy)
09/2008